Press releases
- Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Sage Therapeutics to Participate in Upcoming May Investor Conferences
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
More ▼
Key statistics
On Friday, SAGE Therapeutics Inc (SG7:DUS) closed at 9.80, 0.55% above its 52-week low of 9.74, set on Jun 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.80 |
---|---|
High | 9.80 |
Low | 9.80 |
Bid | 9.77 |
Offer | 9.83 |
Previous close | 9.97 |
Average volume | 340.00 |
---|---|
Shares outstanding | 60.18m |
Free float | 52.68m |
P/E (TTM) | -- |
Market cap | 642.74m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:11 BST.
More ▼